The experimental therapy navenibart was well tolerated and was associated with fewer swelling attacks and improved quality of life in adults with hereditary angioedema (HAE) when given every few months in an early clinical trial, a study showed. “The proof-of-concept data … suggest that infrequent administration of navenibart…